Giant fold gastritis induced by epoprostenol infusion in patients with pulmonary arterial hypertension

Yohei Miura; Masaharu Kataoka; Tomohiro Chiba; Takumi Inami; Hideaki Yoshino; Toru Satoh

doi:10.1253/circj.CJ-18-0349

Giant fold gastritis induced by epoprostenol infusion in patients with pulmonary arterial hypertension

Yohei Miura, Masaharu Kataoka, Tomohiro Chiba, Takumi Inami, Hideaki Yoshino, Toru Satoh

Department of Internal Medicine (Cardiology)

Research output: Contribution to journal › Article

Abstract

Background: Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol. Methods and Results: The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75% in epoprostenol group vs. 0% in control group; P=0.019). Conclusions: Giant fold gastritis may be an important side effect of epoprostenol infusion.

Original language	English
Pages (from-to)	2676-2677
Number of pages	2
Journal	Circulation Journal
Volume	82
Issue number	10
DOIs	https://doi.org/10.1253/circj.CJ-18-0349
Publication status	Published - 2018 Jan 1

Keywords

Epoprostenol
Giant fold gastritis
Pulmonary arterial hypertension
Stomach barium examination

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1253/circj.CJ-18-0349

Fingerprint Dive into the research topics of 'Giant fold gastritis induced by epoprostenol infusion in patients with pulmonary arterial hypertension'. Together they form a unique fingerprint.

Cite this

Miura, Y., Kataoka, M., Chiba, T., Inami, T., Yoshino, H., & Satoh, T. (2018). Giant fold gastritis induced by epoprostenol infusion in patients with pulmonary arterial hypertension. Circulation Journal, 82(10), 2676-2677. https://doi.org/10.1253/circj.CJ-18-0349

@article{b792d4c102a14206b13ec04860decf98,

title = "Giant fold gastritis induced by epoprostenol infusion in patients with pulmonary arterial hypertension",

abstract = "Background: Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol. Methods and Results: The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75% in epoprostenol group vs. 0% in control group; P=0.019). Conclusions: Giant fold gastritis may be an important side effect of epoprostenol infusion.",

keywords = "Epoprostenol, Giant fold gastritis, Pulmonary arterial hypertension, Stomach barium examination",

author = "Yohei Miura and Masaharu Kataoka and Tomohiro Chiba and Takumi Inami and Hideaki Yoshino and Toru Satoh",

year = "2018",

month = jan,

day = "1",

doi = "10.1253/circj.CJ-18-0349",

language = "English",

volume = "82",

pages = "2676--2677",

journal = "Circulation Journal",

issn = "1346-9843",

publisher = "Japanese Circulation Society",

number = "10",

}

TY - JOUR

T1 - Giant fold gastritis induced by epoprostenol infusion in patients with pulmonary arterial hypertension

AU - Miura, Yohei

AU - Kataoka, Masaharu

AU - Chiba, Tomohiro

AU - Inami, Takumi

AU - Yoshino, Hideaki

AU - Satoh, Toru

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol. Methods and Results: The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75% in epoprostenol group vs. 0% in control group; P=0.019). Conclusions: Giant fold gastritis may be an important side effect of epoprostenol infusion.

AB - Background: Epoprostenol infusion is the strongest and most convincing therapeutic strategy for severe pulmonary arterial hypertension (PAH). This study investigated the gastrointestinal side effects of epoprostenol. Methods and Results: The study group of 12 patients treated with epoprostenol (epoprostenol group) and 4 patients without epoprostenol (control group) underwent stomach barium examination, which revealed that the prevalence of giant fold gastritis was significantly higher in the patients treated with epoprostenol (75% in epoprostenol group vs. 0% in control group; P=0.019). Conclusions: Giant fold gastritis may be an important side effect of epoprostenol infusion.

KW - Epoprostenol

KW - Giant fold gastritis

KW - Pulmonary arterial hypertension

KW - Stomach barium examination

UR - http://www.scopus.com/inward/record.url?scp=85054087253&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85054087253&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-18-0349

DO - 10.1253/circj.CJ-18-0349

M3 - Article

C2 - 30135321

AN - SCOPUS:85054087253

VL - 82

SP - 2676

EP - 2677

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 10

ER -